27 / 100
273
Ces Urol 2016; 20(4): 259–274
PŘEHLEDOVÝ ČLÁNEK
28. van Rey F, Heesakkers J.
Solifenacin in multiple sclerosis patients with overactive bladder: a prospective
study. Advances in urology 2011; 2011: 834753.
29. Zámečník L.
Symptomatická terapie roztroušené sklerózy – mikční potíže. In: Havrdová E, editor. Roz‑
troušená skleróza. Praha: Mladá Fronta; 2013. 378–382.
30. Otsuki H, Kosaka T, Nakamura K, et al.
Beta3-adrenoceptor agonist mirabegron is effective for ove‑
ractive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia
in men. International urology and nephrology 2013; 45(1): 53–60.
31. Freeman RM, Adekanmi O, Waterfield MR, et al.
The effect of cannabis on urge incontinence in pati‑
ents with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). International
urogynecology journal and pelvic floor dysfunction 2006; 17(6): 636–641.
32. Preiningerová Lízrová J, Štětkářová I.
Symptomatická terapie roztroušené sklerózy. Léčba spasticity
a porucha chůze. In: Havrdová E, editor. Roztroušená skleróza. Praha: Mladá Fronta; 2013. 370–378.
33. Mahadeva A, Tanasescu R, Gran B.
Urinary tract infections in multiple sclerosis: under-diagnosed and
under-treated? A clinical audit at a large University Hospital. American journal of clinical and experimental
immunology 2014; 3(1): 57–67.
34. Moore KN, Murray S, Malone-Lee J, Wagg A.
Rapid urinalysis assays for the diagnosis of urinary tract
infection. British journal of nursing (Mark Allen Publishing) 2001; 10(15): 995–1001.
35. Rakusa M, Murphy O, McIntyre L, et al.
Testing for urinary tract colonization before high-dose cortico‑
steroid treatment in acute multiple sclerosis relapses: prospective algorithm validation. European journal of
neurology: the official journal of the European Federation of Neurological Societies 2013; 20(3): 448–452.
36. Hanuš T.
Intermitentní katetrizace močového měchýře. Čas Lék Čes 1983; 122: 1135–1137.
37. Krhut J.
Intermitentní katetrizace. In: Krhut J, editor. Neurourologie. Praha Galén; 2005. 37–40.
38. Šámal V, Kyriánová A, Šrám J, Mečl J, Fogl J.
Čistá intermitentní autokatetrizace u neurogenních
dysfunkcí dolních močových cest po spinálním poranění. Porovnávání výsledků při použití hydrofilnch
a standardních PVC katetrů. Ces Urol 2011; 15(4): 229–236.
39. Nicholas R, Young C, Friede T.
Bladder symptoms in multiple sclerosis: a review of pathophysiology
and management. Expert opinion on drug safety 2010; 9(6): 905–915.
40. Krhut J.
Neinvazivní neuromodulace a neurostimulace. In: Krhut J, editor. Neurourologie. Praha Galén;
2005. 46–47.
41. Rejchrt M.
Využití neuromodulace v léčbě dysfunkcí dolních cest močových. Ces Urol 2012; 16(1): 5–12.
42. McClurg D, Ashe RG, Lowe-Strong AS.
Neuromuscular electrical stimulation and the treatment of
lower urinary tract dysfunction in multiple sclerosis-a double blind, placebo controlled, randomised clinical
trial. Neurourology and urodynamics 2008; 27(3): 231–237.
43. Schurch B, Carda S.
Onabotulinumtoxin A and multiple sclerosis. Annals of physical and rehabilitation
medicine 2014; 57(5): 302–314.
44. Krhut J.
Aplikace botulotoxinu do detruzoru. In: Krhut J, editor. Neurourologie. Praha Galén; 2005: 44–46.
45. Schurch B, de Seze M, Denys P, et al.
Botulinum toxin type a is a safe and effective treatment for
neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month
study. The Journal of urology 2005; 174(1): 196–200.
46. Ginsberg D, Gousse A, Keppenne V, et al.
Phase 3 efficacy and tolerability study of onabotulinumto‑
xinA for urinary incontinence from neurogenic detrusor overactivity. The Journal of urology 2012; 187(6):
2131–2139.
47. Sirls LT, Zimmern PE, Leach GE.
Role of limited evaluation and aggressive medical management in
multiple sclerosis: a review of 113 patients. The Journal of urology 1994; 151(4): 946–950.
48. Gough DC.
Enterocystoplasty. BJU international 2001; 88(7): 739–743.